Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient
Authors:
- 19 July 2017
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (9) , 2318-2319
Abstract
Immune checkpoint inhibitors (ICIs) have shown antitumor activity against several malignancies. Nivolumab plus ipilimumab has shown promising efficacy in patients with melanoma and small-cell lung cancer (SCLC) [1–4]. ICI-induced encephalitis is an extremely rare immune-related adverse event and little is known about its clinical course and management [1–4]. We report a case of encephalitis induced by nivolumab plus ipilimumab in an SCLC patient, who showed remarkable improvement upon treatment with rituximab.Keywords
This publication has 5 references indexed in Scilit:
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic CancerJAMA Neurology, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013